Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer

BACKGROUND: Systemic inflammation via host-tumor interactions is currently recognized as a hallmark of cancer. The aim of this study was to evaluate the prognostic value of various combinations of inflammatory factors using preoperative blood, and to assess the clinical significance of our newly developed inflammatory score in colorectal cancer (CRC) patients.

METHOD: In total 477 CRC patients from the discovery and validation cohorts were enrolled in this study. We assessed the predictive impact for recurrence using a combination of nine inflammatory markers in the discovery set, and focused on lymphocyte-C-reactive protein ratio (LCR) to elucidate its prognostic and predictive value for peri-operative risk in both cohorts.

RESULTS: A combination of lymphocytic count along with C-reactive protein levels demonstrated the highest correlation with recurrence compared with other parameters in CRC patients. Lower levels of preoperative LCR significantly correlated with undifferentiated histology, advanced T stage, presence of lymph node metastasis, distant metastasis, and advanced stage classification. Decreased preoperative LCR (using an optimal cut-off threshold of 6000) was an independent prognostic factor for both disease-free survival and overall survival, and emerged as an independent risk factor for postoperative complications and surgical-site infections in CRC patients. Finally, we assessed the clinical feasibility of LCR in an independent validation cohort, and confirmed that decreased preoperative LCR was an independent prognostic factor for both disease-free survival and overall survival, and was an independent predictor for postoperative complications and surgical-site infections in CRC patients.

CONCLUSION: Preoperative LCR is a useful marker for perioperative and postoperative management of CRC patients.

Errataetall:

CommentIn: Ann Surg. 2021 Dec 1;274(6):e689-e690. - PMID 32511130

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:272

Enthalten in:

Annals of surgery - 272(2020), 2 vom: 22. Aug., Seite 342-351

Sprache:

Englisch

Beteiligte Personen:

Okugawa, Yoshinaga [VerfasserIn]
Toiyama, Yuji [VerfasserIn]
Yamamoto, Akira [VerfasserIn]
Shigemori, Tsunehiko [VerfasserIn]
Ide, Shozo [VerfasserIn]
Kitajima, Takahito [VerfasserIn]
Fujikawa, Hiroyuki [VerfasserIn]
Yasuda, Hiromi [VerfasserIn]
Hiro, Junichiro [VerfasserIn]
Yoshiyama, Shigeyuki [VerfasserIn]
Yokoe, Takeshi [VerfasserIn]
Saigusa, Susumu [VerfasserIn]
Tanaka, Koji [VerfasserIn]
Shirai, Yumiko [VerfasserIn]
Kobayashi, Minako [VerfasserIn]
Ohi, Masaki [VerfasserIn]
Araki, Toshimitsu [VerfasserIn]
McMillan, Donald C [VerfasserIn]
Miki, Chikao [VerfasserIn]
Goel, Ajay [VerfasserIn]
Kusunoki, Masato [VerfasserIn]

Links:

Volltext

Themen:

9007-41-4
Biomarkers, Tumor
C-Reactive Protein
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 15.09.2020

Date Revised 29.02.2024

published: Print

CommentIn: Ann Surg. 2021 Dec 1;274(6):e689-e690. - PMID 32511130

Citation Status MEDLINE

doi:

10.1097/SLA.0000000000003239

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM312519419